ABERNETHY MATT 4

4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Neurocrine (NBIX) CFO Matt Abernethy Receives RSU Shares

What Happened

Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences (NBIX), had 2,437 restricted stock units (RSUs) convert to common shares on January 31, 2026 (recorded as derivative conversion/exercise). The company withheld 1,368 of those shares to satisfy tax withholding obligations at a per-share value of $136.06, producing a withholding value of $186,130. Net shares delivered to Abernethy were 1,069 (2,437 vested − 1,368 withheld). No open-market sale was reported.

Key Details

Transaction date: January 31, 2026; Form 4 filed February 3, 2026 (timely).
Vested/converted: 2,437 RSU shares at $0.00 (no exercise price).
Tax withholding: 1,368 shares withheld at $136.06 per share, total $186,130.
Net shares received: 1,069 shares.
Shares owned after transaction: not specified in the filing.
Notable footnotes:
- F1: Filing notes aggregate includes 218 shares purchased on Aug 29, 2025 via the company ESPP.
- F2: Withholding was done by the company to satisfy tax withholding on RSU vesting (no open-market sale).
- F3: Each RSU equals the right to one share.
- F4: The RSU award was granted Jan 31, 2022 and vested in annual tranches, with 2,437 shares vesting Jan 31, 2026.

Context

This was an RSU vesting event (conversion of a derivative award), not an opportunistic open-market sale or new purchase. The withholding of shares to cover taxes is a common administrative step and does not necessarily signal a change in insider conviction. The filing appears timely (filed within the Form 4 reporting window).

Form 4

Period: 2026-01-31

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-31+2,437→ 38,465 total
Tax Payment
Common Stock
[F2]
2026-01-31$136.06/sh−1,368$186,130→ 37,097 total
Exercise/Conversion
Restricted Stock Unit
[F3][F4]
2026-01-31−2,437→ 0 total
→ Common Stock (2,437 underlying)

Footnotes (4)

[F1]Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
[F2]Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
[F3]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F4]This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and vested as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.

Signature

/s/ Darin Lippoldt, Attorney-in-Fact|2026-02-03

1 file